Multimodal Approach of Pulmonary Artery Intimal Sarcoma: A Single-Institution Experience.

Area of Science:

• Cardiovascular Surgery
• Thoracic Oncology
• Pulmonary Hypertension

Background:

• Pulmonary artery sarcoma (PAS) is a rare malignancy with a historically poor prognosis.
• Current treatment primarily relies on surgical resection (pneumonectomy or PEA).
• Untreated PAS is associated with extremely limited survival.

Purpose of the Study:

• To evaluate the feasibility and outcomes of a multimodal treatment approach for pulmonary artery sarcoma.
• To assess the impact of pulmonary endarterectomy (PEA) combined with adjuvant therapies on patient survival and quality of life.

Main Methods:

• Retrospective analysis of 12 patients diagnosed with PAS who underwent PEA between 2010 and 2016.
• Patients received adjuvant chemotherapy (doxorubicin and ifosfamide) and/or radiotherapy post-surgery.
• Data collected on patient demographics, symptom duration, treatment details, and outcomes.

Main Results:

• Seven out of 10 patients who received adjuvant therapy are alive, with 5 disease-free at 4-55+ months.
• Four patients experienced disease progression and mortality.
• The multimodal approach was feasible, with chemotherapy initiated a median of 42 days post-surgery.

Conclusions:

• A multimodal strategy integrating PEA, chemotherapy, and radiotherapy is a viable option for select PAS patients.
• Individualized treatment plans are crucial, considering tumor extent and patient condition.
• This approach may enhance both quality of life by managing pulmonary hypertension and overall life expectancy.